© Globe Newswire
19.01.2026
GBT
LISTED
EURONEXT
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2025
News Preview
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE...
Themefolio
Profiler
Peergroup
© BusinessWire
19.01.2026
QGEN
LISTED
NYSE
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
News Preview
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025.
Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 Londo...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
19.01.2026
GH
LISTED
NASDAQ
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.
Under the multi-year collaboration agreemen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
19.01.2026
TELO
LISTED
TSX
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
News Preview
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") is pleased to announce a non-brokered private placement offering of secured convertible debentures ("D...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2026
HBFG
LISTED
CSE
Happy Belly Food Group's Yolks Breakfast Announces Grand Opening of Its First Quebec Location in Montreal
News Preview
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce the grand opening of Yolks Breakfast's first Quebec location at 44 Brunswick Blvd, Unit 101, Dollard-des-Ormeaux, Montreal, Queb...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
LABS
LISTED
TSX
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
News Preview
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
VME
LISTED
XETR
45 CET/CEST - Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
News Preview
PRESS RELEASE
Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
Rellingen, 19 January 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, will conduct the announced ex-vivo study on vital lungs in cooperation with Saarland University and Hann......
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
9926
LISTED
HKSE
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
News Preview
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Pro...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
VME
LISTED
XETR
Ex-vivo-Lungenstudie markiert Meilenstein für Forschung und Zulassung
News Preview
PRESSEMITTEILUNG
Viromed Medical AG: Ex-vivo-Lungenstudie markiert Meilenstein für Forschung und Zulassung
Rellingen, 19. Januar 2026 – Die Viromed Medical AG („Viromed“; ISIN: DE000A40ZVN7), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, führt die angekündigte Ex-vivo-Studie an vitalen Lungen in Zusammenarbeit mit der Unive......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
STMN
LISTED
SIX
Straumann Group Ganzjahresergebnisse 2025 Webcast
News Preview
Straumann Holding AG
/ Schlagwort(e): Jahresergebnis/Quartalsergebnis
Einladung: Straumann Group Ganzjahresergebnisse 2025 Webcast
19.01.2026 / 11:00 CET/CEST
Datum: Mittwoch, 18. Februar 2026
Zeit: 10:30 – 11:30 Uhr MEZ
Die Straumann Group wird ihre Ganzjahresergebnisse 2025 am Mittwoch, 18. Februar 2026, geg......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
IMC
LISTED
ASX
Immuron Reports Continued Sales Growth
News Preview
Sales Highlights (unaudited):...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
19.01.2026
ILM1
LISTED
XETR
Medios AG enters market for medicinal cannabis
News Preview
Press release
Medios AG enters market for medicinal cannabis
Expansion of product portfolio with medicinal cannabis
Medios obtains exclusive distribution rights for Bedrocan® products in agreed European markets
Entry into an attractive growth market and strengthening expertise in existing indication areas
Berlin, January 19, 2026 – The Medios G......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ILM1
LISTED
XETR
Medios AG steigt in den Markt für Medizinalcannabis ein
News Preview
Pressemitteilung
Medios AG steigt in den Markt für Medizinalcannabis ein
Erweiterung des Produktportfolios mit Medizinalcannabis
Medios erhält Exklusivvertriebsrechte für die Bedrocan®-Produkte in vereinbarten europäischen Märkten
Eintritt in attraktiven Wachstumsmarkt und Stärkung der Kompetenz in bestehenden Indikationsgebieten
Berlin, 19. Ja......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
45650
LISTED
XJPX
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
News Preview
Tokyo, Japan and Cambridge, UK, 19 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that positive top-line results were obtained from a Phase 3 study conducted in South Korea evaluating daridorexant 50 mg in adult and elderly patients with insomnia. The Company plans to submit a marketing authorization applicatio...
Themefolio
Profiler
Peergroup
© BusinessWire
19.01.2026
45680
LISTED
XJPX
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
News Preview
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.
ENHERTU is a specifically engineered HER2 directed DXd antibod...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
2696
LISTED
HKSE
Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
News Preview
SAN FRANCISCO, 19. Januar 2026 /PRNewswire/ -- Die 44. J.P. Morgan Healthcare Conference (JPMHC) fand erfolgreich vom 12. bis 15. Januar in San Francisco, Vereinigte Staaten, statt. Am 15. Januar (PST) hielt Dr. Jason Zhu, Geschäftsführender Direktor und Geschäftsführer von Shanghai Henlius Biotech, Inc. (2696.HK), eine Grundsatzrede, in der er di...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
OXUR
LISTED
EURONEXT
Oxurion kondigt de tijdelijke opschorting aan van het financieringsprogramma bestemd voor investeringen in digitale activa en crypto-activa
News Preview
Leuven, BELGIË – 19 januari 2026 – 8u00 CET Oxurion NV (Euronext Brussel: OXUR), een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, heeft het investeringsproject in digitale activa en crypto-activa, zoals op 1 december 2025 aan de markt werd meegedeeld, herbekeken. Dit project had tot doel een alternatieve activakl...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
OXUR
LISTED
EURONEXT
Oxurion announces the temporary suspension of the financing programme dedicated to investments in digital assets and crypto-assets
News Preview
Leuven, BELGIUM – January 19, 2026 – 08:00 AM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, has reviewed the investment project in digital assets and crypto-assets, as communicated to the market on 1 December 2025. The objective of this project was to consider an alternative asset clas...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
OXUR
LISTED
EURONEXT
Oxurion annonce la suspension temporaire du programme de financement dédié à des investissements dans les actifs numériques et crypto-actifs
News Preview
Louvain, BELGIQUE – 19 janvier 2026 – 8h00, Oxurion NV (Euronext Bruxelles : OXUR), société de sous-traitance pharmaceutique basée à Louvain, a réexaminé le projet d'investissement dans des actifs numériques et des crypto-actifs, tel que communiqué au marché le 1er d&eac...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
BAVA
LISTED
CPH
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
News Preview
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
PPGN
LISTED
SIX
PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
News Preview
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful cl......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
IBAB
LISTED
EURONEXT
IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems
News Preview
Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announced that it has signed a contract with the University of Texas MD Anderson Cancer Center, ranked #1 in cancer care by...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
XPHY
LISTED
CSE
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
News Preview
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has completed and received preliminary results from its comparative pharmacokinetics ("...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Directorate Change
News Preview
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SE...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
PPGN
LISTED
SIX
PolyPeptide Successfully Closes Financial Year 2025 With Strong Revenue Growth and Marked Improvement in Profitability
News Preview
BAAR, CH / ACCESS Newswire / January 19, 2026 / PolyPeptide Group AG (SIX:PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its financial year 2025.HighlightsPolyPeptide closes financial year 2025 with strong revenue growth and a marked improvement in profitability, in li...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
SPRB
LISTED
OTC
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
News Preview
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
2359
LISTED
HKSE
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
News Preview
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Pro...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2026
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2026
OGN
LISTED
NYSE
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON® (etonogestrel implant), which is indicated for use by women of reproductive pot...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2026
AIDR
LISTED
CSE
ROCKET DOCTOR AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT
News Preview
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part,...
Themefolio
Profiler
Peergroup
© Newsfile
17.01.2026
DTR
LISTED
CSE
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of i...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
VTGN
LISTED
NASDAQ
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). Vistagen is a clinical-stage biopharmaceutical company.
For more information, submit a form,...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
DBV
LISTED
EURONEXT
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
News Preview
Châtillon, France, January 16, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
DMAC
LISTED
NASDAQ
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-e...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
RPTX
LISTED
NASDAQ
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
News Preview
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ATOS
LISTED
NASDAQ
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
News Preview
Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease DesignationSEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CLC
LISTED
CSE
Christina Lake Cannabis Announces Sale of Bare Land
News Preview
Christina Lake Cannabis Corp. (CSE: CLC) sold 99 acres of non-core land in Christina Lake, BC for $551,000; proceeds support working capital....
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an agg...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The in...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
MTVA
LISTED
NASDAQ
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
QTRX
LISTED
NASDAQ
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the “Inducement Grants”) were made to four employees in connection with the commencement of their employment. The...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
LFCR
LISTED
NASDAQ
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
VTGN
LISTED
NASDAQ
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
HKPD
LISTED
NASDAQ
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
News Preview
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq'...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
BAYN
LISTED
XETR
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
News Preview
The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits du...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ZBIO
LISTED
NASDAQ
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
XENE
LISTED
NASDAQ
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-o...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CNTX
LISTED
NASDAQ
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CAMP
LISTED
NASDAQ
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
News Preview
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.01.2026
TTNP
LISTED
NASDAQ
Black Titan Secures $200 Million from a U.S.-Based Institutional Investor to Scale Its DAT+ Vision
News Preview
NEW YORK, NY / ACCESS Newswire / January 16, 2026 / Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced that it has entered into a securities purchase agreement with a U.S.-based institutional investor for a convertible note financing facility of up to $200 million. This significant capital com...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix's commercial PSMA-PET...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ABBV
LISTED
EURONEXT
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
News Preview
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next stepsNORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecif...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
GMAB
LISTED
NASDAQ
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
News Preview
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additiona...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
FFNT
LISTED
CSE
CSE Bulletin: Delist - 4Front Ventures Corp. (FFNT)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 16 janvier/January 2026) - The subordinate voting shares of 4Front Ventures Corp. will be delisted from the CSE at market close today, January 16, 2026. 4Front Ventures Corp. is currently suspended. See Bulletin 2025-0510. _________________________________ Les actions &...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
News Preview
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging age...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
AGL
LISTED
NYSE
Deadline Alert: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming March 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class Peri...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
